ICER’s second annual Launch Launch Price and Access Report, developed this year in partnership with West Health, found that the median price for drugs launched in 2025 was $250,000. But that high ...
Dren Bio is a privately held, clinical-stage biotechnology company developing antibody therapeutics for cancer, autoimmune and other serious diseases. Proceeds from the financing will support ...
Astellas Pharma has signed an option and licensing agreement with Australian biotech Audax Biosciences for DAX-044 - a preclinical immuno-oncology candidate built on Audax's AVIKINE platform. The deal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results